MC1R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-20. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Elastic cartilage, fibroelastic cartilage or yellow fibrocartilage is a type of cartilage present in the pinnae (auricles) of the ear giving it shape, provides shape for the lateral region of the external auditory meatus, medial part of the auditory canal Eustachian tube, corniculate and cuneiform laryngeal cartilages, and the epiglottis. It contains elastic fiber networks and collagen type II fibers. The principal protein is elastin.
One study found that the elimination half-life of hydroxyzine in adults was as short as 3 hours, but this may have just been due to methodological limitations. Although hydroxyzine has a long elimination half-life and acts, in-vivo, as an antihistamine for as long as 24 hours, the predominant CNS effects of hydroxyzine and other antihistamines with long half-lives seem to diminish after 8 hours. Administration in geriatrics differs from the administration of hydroxyzine in younger patients; according to the FDA, there have not been significant studies made (2004), which include population groups over 65, which provide a distinction between elderly aged patients and other younger groups. Hydroxyzine should be administered carefully in the elderly with consideration given to possible reduced elimination.
=== Trump accounts and contribution pilot program === The law creates Trump accounts, a type of tax-advantaged savings investment account. Any individual is allowed to contribute to a child's account, up to $5,000 per year per child. Employers are allowed to contribute to their employees' accounts and their employees' children's accounts, up to $2,500 per year. Contributions by an employer count against the $5,000 annual limit per child, but contributions by the federal government do not. As an exception to the annual limit, tax-exempt organizations are allowed to contribute an unlimited amount into a child's account. Contributions into a child's account are allowed until the end of the end of the year in which the child turns 18. The federal government will contribute $1,000 into a Trump account for each U.S. citizen child with a social security number who was born between January 1, 2025, and December 31, 2028. Funds in the account must be invested in mutual funds or exchange-traded funds that mirror the S&P 500 or another U.S. stock index. Investment earnings are tax-deferred. A child with a qualified disability is allowed to rollover the funds into an ABLE account when they reach age 17. For other children, rollovers and withdrawals from the account are allowed starting on the January 1 of the year in which the child turns age 18. When the child reaches age 18, the funds will be rolled into a traditional IRA.
In July 2024, the Institute for Strategic Dialogue reported that an organized neo-Nazi TikTok network promoting neo-Nazi propaganda, including Europa: The Last Battle, was receiving millions of views and was having its content promoted by TikTok's algorithm. In September 2024, Sky News reported that clips of Adolf Hitler's speeches with added music were attracting high levels of engagement on TikTok. Although they were removed by TikTok after the report, mixing audio remains an effective way to evade content moderation on many platforms. In July 2025, Media Matters reported that Google's Veo 3 text-to-video model for AI-generated content is being used to generate large numbers of dehumanizing and violent videos with racist and antisemitic tropes which are being shared on TikTok.
=== Category:EC 1.12 (act on hydrogen as a donor) === Category:EC 1.12.1 (with NAD+ or NADP+ as acceptor) Category:EC 1.12.2 (with a cytochrome as acceptor) Category:EC 1.12.5 (with a quinone or similar compound as acceptor) Category:EC 1.12.7 (with an iron–sulfur protein as acceptor) Category:EC 1.12.98 (with other known acceptors) Category:EC 1.12.99 (with other acceptors)
Sources: en.wikipedia.org
==== Interpellation and censure of Iber Maraví ==== The Labor Minister Iber Maraví has been accused of having links to the Shining Path, claims which he has denied. Police reports from 1980, 1981, and 2004 suspected that Maraví had ties to the Shining Path and Conare-Sutep, a teacher union linked with MOVADEF. Maraví maintained his innocence, stating that he has no criminal or judicial record and that the police used torture against detainees to get them to falsely implicate themselves or others as terrorists. Two of the witnesses who accused Maraví were convicted of terrorism and escaped from jail less than a year later along with several notorious Shining Path leaders. Maraví has acknowledged that his wife and mother-in-law signed forms to register MOVADEF as a political party. However, he claims that the event occurred without his consent. Maraví has claimed that the allegations against him are devoid of substance and were designed to tarnish his reputation. He stated that he has openly condemned any terrorist act and expressed his conviction for respecting institutions and democracy. Initially, Prime Minister Guido Bellido asked for Maraví to resign. However, the Prime Minister later changed his mind and said that he would use the question of confidence to defend Maraví from impeachment. Following this, Keiko Fujimori, the leader of Popular Force accused Castillo of leading a terrorist government. Subsequently, Maraví announced that he would undertake legal action against Keiko.
In 2023, LECO and Cal State LA worked in tandem to launch a new chemical analysis lab. The new lab would work with both undergraduate and graduate students within the Department of Chemistry and Biochemistry. Since 2025, the cement industry has been working to reduce carbon emissions and adopt more sustainable production methods. The LECO Corporation provides analytical instrumentation to support that transition. Its portfolio has included calorimeters, thermogravimetric analyzers, and combustion analyzers that measure factors such as calorific value, moisture, ash, carbon, sulfur, and loss on ignition in fuels and raw materials. This helps cement producers evaluate alternative inputs, monitor performance, and improve operational efficiency while reducing environmental impact. Research was also conducted at Oxford by scholars within the Department of Materials which tested the LECO process of testing solar cells and silicon materials.
On December 13, 2018, the teaser of the film Black Antenna featuring the song "Rainier Fog" was released on Alice in Chains' official YouTube channel, with drummer Sean Kinney stating; "We've always toyed with the idea of creating videos for every song on one of our albums. Not only did we do that for Rainier Fog, it got totally out of hand and we made a whole goddamn movie. Everything that will be seen in the videos will be footage from Black Antenna to preface the complete film's release." "Rainier Fog" was released as a single on February 26, 2019. The official trailer for Black Antenna was released on Alice in Chains' YouTube Channel on February 28, 2019. Besides a 90-minute film, a 10-part web-series focused on each track from the album was planned. Episodes 1 and 2, "The One You Know" and "Rainier Fog", respectively, were released on March 7, 2019. The tenth and last episode, "All I Am", was released on July 17, 2019. The official music video for "Rainier Fog" was released on YouTube on May 15, 2019, and was co-directed by Alice in Chains and Peter Darley Miller, who also directed the band's 2013 mockumentary, AIC 23. On December 1, 2020, Alice in Chains was honored with the Founders Award from Seattle's Museum of Pop Culture. The benefit concert featured tribute performances from artists such as Ann Wilson, Korn, Metallica, Fishbone, Dallas Green, Billy Corgan, Tad Doyle, members of Soundgarden and Pearl Jam, among others. The event was made available for streaming for free and raised more than $600,000 for the museum in its first night.
=== 1950–60s === After the war, some of the inventions found new applications. The first transistor radio was released in 1954, and its manufacturing process made use of vacuum pumps. The first integrated circuit or "chip" came to the market at the end of the 1950s, and vacuum pumps again played an important role in their production. These early inventions were Edwards' first steps into the electronics and semiconductors industry, which is to this day the company's biggest market. Chips became increasingly small throughout the decades, increasing the importance of vacuum purity.
β-Carotene (beta-carotene) is an organic, strongly colored red-orange pigment abundant in fungi, plants, and fruits. It is a member of the carotenes, which are terpenoids (isoprenoids), synthesized biochemically from eight isoprene units and thus having 40 carbons. Dietary β-carotene is a provitamin compound, converting in the body to retinol (vitamin A). In foods, it has rich content in carrots, pumpkin, spinach, and sweet potato. It is used as a dietary supplement and may be prescribed to treat erythropoietic protoporphyria, an inherited condition of sunlight sensitivity. β-carotene is the most common carotenoid in plants. When used as a food coloring, it has the E number E160a. The structure was deduced in 1930. Isolation of β-carotene from fruits abundant in carotenoids is commonly done using column chromatography. It is industrially extracted from richer sources such as the algae Dunaliella salina. The separation of β-carotene from the mixture of other carotenoids is based on the polarity of a compound. β-Carotene is a non-polar compound, so it is separated with a non-polar solvent such as hexane. Being highly conjugated, it is deeply colored, and as a hydrocarbon lacking functional groups, it is lipophilic.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.